

## GLP-1 Pipeline Update: May 2025

As the GLP-1 pipeline continues to grow, Prime actively monitors this emerging landscape and provides a credible clinical snapshot of what is on the horizon. The table below displays the earliest potential approval dates of the agents listed. Dates are based on manufacturer published announcements or communications or are estimated based on study completion dates and may change as more information becomes available.

Drug / Dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	OSA + Obesity or overweight	OA of knee + Obesity or overweight	Chronic HF + Obesity	CKD + Obesity or overweight	MASH	Alzheimer's disease
<b>Manufacturer: AstraZeneca</b>													
exenatide (Byetta, Bydureon Bcise) / SC	FDA-approved (Byetta <i>only</i> ages ≥ 10 years)												
<b>Manufacturer: Eli Lilly</b>													
dulaglutide (Trulicity) / SC	FDA-approved (ages ≥ 10 years)		FDA-approved										
tirzepatide (Mounjaro) / SC	FDA-approved												
tirzepatide (Zepbound) / SC		FDA-approved						FDA-approved		FDA submission withdrawn	2027		
orforglipron / oral	2027	2026						2027					
retatrutide / SC	2027	2027		2027		2027		2027	2027				
<b>Manufacturer: Novo Nordisk</b>													
liraglutide (Victoza)* / SC	FDA-approved (ages ≥ 10 years)		FDA-approved										
liraglutide (Saxenda) / SC		FDA-approved (ages ≥ 12 years)											
liraglutide-insulin degludec (Xultophy) / SC	FDA-approved												
semaglutide (Rybelsus) 1.5–14 mg / oral	FDA-approved		FDA decision Oct. 2025										2027

Drug / Dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	T2DM + PAD	Diabetic nephropathy	Diabetic retinopathy	OSA + Obesity or overweight	OA of knee + Obesity or overweight	Chronic HF + Obesity	CKD + Obesity or overweight	MASH	Alzheimer's disease
Manufacturer: Novo Nordisk (continued)													
semaglutide 25 mg (Wegovy) / oral		FDA decision 4Q2025		FDA decision 4Q2025									
semaglutide 25 mg, 50 mg (NN9924) /oral	2026												
semaglutide 1 mg, 2 mg (Ozempic) / SC	FDA-approved		FDA-approved		FDA decision 2025	FDA-approved	2027						
semaglutide 1.7 mg, 2.4 mg (Wegovy) / SC		FDA-approved (ages ≥ 12 years)		FDA-approved					2026	FDA decision 4Q2025		2.4 mg FDA decision 3Q2025	
semaglutide + insulin icodec / SC	2026												
cagrilintide + semaglutide / SC	2027	2027											
Manufacturer: Sanofi													
lixisenatide + insulin glargine (Soliqua) / SC	FDA-approved												
Manufacturer: Zealand, Boehringer Ingelheim													
survodutide / SC												2027	

\*generics available

## Glossary

**CKD** Chronic kidney disease

**CVD** Cardiovascular disease

**FDA** Food and Drug Administration

**GLP-1** Glucagon-like peptide-1 receptor agonist

**HF** Heart failure

**MASH** Metabolic dysfunction-associated steatohepatitis

**OA** Osteoarthritis

**OSA** Obstructive sleep apnea

**PAD** Peripheral arterial disease

**SC** Subcutaneous

**T2DM** Type 2 diabetes mellitus

## Disclaimer

*The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.*

*All brand names are property of their respective owners.*